Localized low-dose rhBMP-2 is effective at promoting bone regeneration in mandibular segmental defects
© 2018 Wiley Periodicals, Inc..
At least 26% of recent battlefield injuries are to the craniomaxillofacial (CMF) region. Recombinant human bone morphogenetic protein 2 (rhBMP-2) is used to treat CMF open fractures, but several complications have been associated with its use. This study tested the efficacy and safety of a lower (30% recommended) dose of rhBMP-2 to treat mandibular fractures. rhBMP-2 delivered via a polyurethane (PUR) and hydroxyapatite/β-tricalcium phosphate (Mastergraft®) scaffold was evaluated in a 2 cm segmental mandibular defect in minipigs. Bone regeneration was analyzed at 4, 8, and 12 weeks postsurgery using clinical computed tomography (CT) and rhBMP-2, and inflammatory marker concentrations were analyzed in serum and surgery-site drain effluent. CT scans revealed that pigs treated with PUR-Mastergraft® + rhBMP-2 had complete bone bridging, while the negative control group showed incomplete bone-bridging (n = 6). Volumetric analysis of regenerated bone showed that the PUR-Mastergraft® + rhBMP-2 treatment generated significantly more bone than control by 4 weeks, a trend that continued through 12 weeks. Variations in inflammatory analytes were detected in drain effluent samples and saliva but not in serum, suggesting a localized healing response. Importantly, the rhBMP-2 group did not exhibit an excessive increase in inflammatory analytes compared to control. Treatment with low-dose rhBMP-2 increases bone regeneration capacity in pigs with mandibular continuity defects and restores bone quality. Negative complications from rhBMP-2, such as excessive inflammatory analyte levels, were not observed. Together, these results suggest that treatment with low-dose rhBMP-2 is efficacious and may improve safety when treating CMF open fractures. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 107B: 1491-1503, 2019.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:107 |
|---|---|
| Enthalten in: |
Journal of biomedical materials research. Part B, Applied biomaterials - 107(2019), 5 vom: 15. Juli, Seite 1491-1503 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Carlisle, Patricia [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.08.2020 Date Revised 30.09.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jbm.b.34241 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM289015766 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM289015766 | ||
| 003 | DE-627 | ||
| 005 | 20231225061625.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jbm.b.34241 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0963.xml |
| 035 | |a (DE-627)NLM289015766 | ||
| 035 | |a (NLM)30265782 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carlisle, Patricia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Localized low-dose rhBMP-2 is effective at promoting bone regeneration in mandibular segmental defects |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.08.2020 | ||
| 500 | |a Date Revised 30.09.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2018 Wiley Periodicals, Inc. | ||
| 520 | |a At least 26% of recent battlefield injuries are to the craniomaxillofacial (CMF) region. Recombinant human bone morphogenetic protein 2 (rhBMP-2) is used to treat CMF open fractures, but several complications have been associated with its use. This study tested the efficacy and safety of a lower (30% recommended) dose of rhBMP-2 to treat mandibular fractures. rhBMP-2 delivered via a polyurethane (PUR) and hydroxyapatite/β-tricalcium phosphate (Mastergraft®) scaffold was evaluated in a 2 cm segmental mandibular defect in minipigs. Bone regeneration was analyzed at 4, 8, and 12 weeks postsurgery using clinical computed tomography (CT) and rhBMP-2, and inflammatory marker concentrations were analyzed in serum and surgery-site drain effluent. CT scans revealed that pigs treated with PUR-Mastergraft® + rhBMP-2 had complete bone bridging, while the negative control group showed incomplete bone-bridging (n = 6). Volumetric analysis of regenerated bone showed that the PUR-Mastergraft® + rhBMP-2 treatment generated significantly more bone than control by 4 weeks, a trend that continued through 12 weeks. Variations in inflammatory analytes were detected in drain effluent samples and saliva but not in serum, suggesting a localized healing response. Importantly, the rhBMP-2 group did not exhibit an excessive increase in inflammatory analytes compared to control. Treatment with low-dose rhBMP-2 increases bone regeneration capacity in pigs with mandibular continuity defects and restores bone quality. Negative complications from rhBMP-2, such as excessive inflammatory analyte levels, were not observed. Together, these results suggest that treatment with low-dose rhBMP-2 is efficacious and may improve safety when treating CMF open fractures. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 107B: 1491-1503, 2019 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a bone regeneration | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a mandible | |
| 650 | 4 | |a minipig | |
| 650 | 4 | |a rhBMP-2 | |
| 650 | 7 | |a BMP2 protein, human |2 NLM | |
| 650 | 7 | |a Bone Morphogenetic Protein 2 |2 NLM | |
| 650 | 7 | |a Calcium Phosphates |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 650 | 7 | |a beta-tricalcium phosphate |2 NLM | |
| 650 | 7 | |a Durapatite |2 NLM | |
| 650 | 7 | |a 91D9GV0Z28 |2 NLM | |
| 700 | 1 | |a Guda, Teja |e verfasserin |4 aut | |
| 700 | 1 | |a Silliman, David T |e verfasserin |4 aut | |
| 700 | 1 | |a Burdette, Alexander J |e verfasserin |4 aut | |
| 700 | 1 | |a Talley, Anne D |e verfasserin |4 aut | |
| 700 | 1 | |a Alvarez, Rene |e verfasserin |4 aut | |
| 700 | 1 | |a Tucker, David |e verfasserin |4 aut | |
| 700 | 1 | |a Hale, Robert G |e verfasserin |4 aut | |
| 700 | 1 | |a Guelcher, Scott A |e verfasserin |4 aut | |
| 700 | 1 | |a BrownBaer, Pamela R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of biomedical materials research. Part B, Applied biomaterials |d 2003 |g 107(2019), 5 vom: 15. Juli, Seite 1491-1503 |w (DE-627)NLM122587375 |x 1552-4981 |7 nnns |
| 773 | 1 | 8 | |g volume:107 |g year:2019 |g number:5 |g day:15 |g month:07 |g pages:1491-1503 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jbm.b.34241 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 107 |j 2019 |e 5 |b 15 |c 07 |h 1491-1503 | ||